至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Removing a light-chain missing byproduct by MMC ImpRes mixed-mode chromatography under weak partitioning mode in purifying a WuXiBody-based bispecific antibody

Protein Expr Purif. 2021-06; 
Ting Zhang, Yan Wan, Jiwei Duan, Yifeng Li
Products/Services Used Details Operation
Nucleic Acid Purification & Analysis … Iodoacetamide and SDS were purchased from Sigma-Aldrich (St. Louis, MO, USA). Precast SurePAGE 4-12% gradient Bis-Tris gels, liquid container and eStain LG protein destainer were purchased from Genscript (Nanjing, China) … Get A Quote

摘要

WuXiBody is a bispecific antibody (bsAb) platform developed by WuXi Biologics. Its key feature is the replacement of one parental antibody's CH1/CL region with the T cell receptor (TCR) constant domain, a design that promotes cognate heavy chain (HC)-light chain (LC) pairing. BsAbs based on WuXiBody can adopt either asymmetric or symmetric format. For purifying a WuXiBody-based symmetric bsAb, we identified a LC-missing species as a major byproduct. While for bsAbs based on other platforms removal of such byproduct can pose considerable challenge to the downstream team, in this case WuXiBody's unique design makes separation relatively straightforward. We previously showed that Capto MMC ImpRes mixed-mode chroma... More

关键词

Bispecific antibody (bsAb), Capto MMC ImpRes, Light chain (LC)-missing byproduct, Mixed-mode chromatography, Weak partitioning mode, WuXiBody